CN106399503A - Primers, kit and method for detection of SJS/TEN caused by AEDs - Google Patents

Primers, kit and method for detection of SJS/TEN caused by AEDs Download PDF

Info

Publication number
CN106399503A
CN106399503A CN201610832567.4A CN201610832567A CN106399503A CN 106399503 A CN106399503 A CN 106399503A CN 201610832567 A CN201610832567 A CN 201610832567A CN 106399503 A CN106399503 A CN 106399503A
Authority
CN
China
Prior art keywords
hla
gene
sjs
primer
aeds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201610832567.4A
Other languages
Chinese (zh)
Inventor
廖卫平
石奕武
郑仲征
杜金伟
易咏红
民福利
杜可明
廖宽镇
潘捷
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shenzhen Medicine Co Ltd Shuo Di Becken
Original Assignee
Shenzhen Medicine Co Ltd Shuo Di Becken
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenzhen Medicine Co Ltd Shuo Di Becken filed Critical Shenzhen Medicine Co Ltd Shuo Di Becken
Priority to CN201610832567.4A priority Critical patent/CN106399503A/en
Publication of CN106399503A publication Critical patent/CN106399503A/en
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention belongs to the technical field of gene engineering, and discloses a primer composition for detection of SJS/TEN caused by AEDs, a kit containing the primer composition and a method for detection of the SJS/TEN caused by the AEDs. The SJS/TEN caused by taking the AEDs and an AEDs tolerance sample are subjected to HLA-A and HLA-B locus Sanger sequencing typing, on the basis, primers for specific amplification of an HLA-A*24:02 gene and an HLA-B*15:02 gene are designed, and thus the method for detection of the SJS/TEN caused by the AEDs is designed. The method is rapid, simple, accurate, sensitive and intuitive, and the experimental cost is low. Through combined detection of the HLA-A*24:02 gene and the HLA-B*15:02 gene, the SJS/TEN caused by the AEDs is predicted, and the incidence rate of the SJS/TEN in Southern Han nationality population can be greatly reduced.

Description

For detecting primer, test kit and the method for SJS/TEN that AEDs causes
Technical field
The present invention relates to gene engineering technology field is and in particular to be used for detecting the primer of SJS/TEN, examination that AEDs causes Agent box and method.
Background technology
Aromatic series antiepileptic (aromatic antiepileptic drugs, AEDs) is to cause skin-type bad anti- Answer one of the common factors of (cutaneous adverse drug reactions, cADRs).CADRs includes slight speckle mound Rash (maculopapular exanthema, MPE), and dermoreaction (the severe cutaneous of serious threat to life Reaction, SCR), such as Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (toxic Epidermal necrolysis, TEN) and drug-induced hypersensitivity syndrome (drug hypersensitivity syndrome, HSS).SJS and TEN belongs to same spectrum of disease, can be according to the degree different classifications of mucosa or skin exfoliation, SJS skin exfoliation face The long-pending ratio with the skin gross area<10%, and TEN>30%.Skin-type untoward reaction the lighter affects the therapeutic effect of medicine, weight Person is lethal, and fatality rate reaches more than 30%, and the wherein fatality rate of SJS/TEN is up to 40%.Serious skin reaction more than 90% Occur two months after medication, no dose dependent, no predictability.Aromatic series antiepileptic AEDs, such as carbamazepine (carbamazepine, CBZ), lamotrigine (lamotrigine, LTG) and phenytoin (phenytoin, PHT) are clinical conventional In treatment epilepsy and neural class disease, three kinds of drug induced Stevens-Johnson syndrome (SJS) incidence rates are about 35.8/10,000, south China Chinese Han Population is even more group of people at high risk.
HLA gene is located at human chromosomal 6p21.3, is about 4,000Kb, is the genetic polymorphism system of most complex human, Obvious population characteristics in distribution in different races or same race's different groups.In southern Chinese Han Population, HLA- There is strong correlation in the SJS/TEN that B*1502 and carbamazepine (CBZ) lead to, U.S. FDA recommended asian ancestry before taking CBZ, Carry out HLA-B*15:02 detection, to avoid the generation of SJS/TEN.The HLA related gene of the SJS/TEN that LTG, PHT lead to is still Not clear and definite.Additionally, southern Chinese Han Population HLA-B*15:02 negative SJS Proportion of patients is up to 30.4%, therefore, except HLA-B*15: Outside 02, it is understood that there may be other risks and assumptions, if before medication, carrying out the detection of risks and assumptions, for effective reduction medicine High risk provides possibility.
Content of the invention
The present invention is directed to drawbacks described above present in prior art, using case-control study method, draws to taking AEDs SJS/TEN the and AEDs tolerance sample rising carries out HLA-A site and HLA-B site Sanger sequencing and typing, sets on this basis Count and be used for specific amplification HLA-A*24:02 gene and HLA-B*15:The primer of 02 gene, and thus devise AEDs is drawn The method that the SJS/TEN rising is detected.The method of the present invention is quick, easy, accurate, sensitive, directly perceived, and experimental cost is low.
For this reason, one aspect of the present invention provides a kind of combination of the primer for detecting SJS/TEN that AEDs causes, it is by sequence Primer composition shown in row 1-4, for specific amplification HLA-A*24:02 gene and HLA-B*15:02 gene.
In a preferred embodiment of the present invention, this primer combination is made up of 2 groups of primers further, and the 1st group by sequence 1 He Primer composition shown in 2, for specific amplification HLA-A*24:02 gene, the 2nd group of primer shown in sequence 3 and 4 forms, For specific amplification HLA-B*15:02 gene.
In further preferred embodiment of the present invention, the concentration of every primer is 10pmol/l.
Another aspect of the present invention provides a kind of test kit for detecting SJS/TEN that AEDs causes, and it comprises this Bright described primer combination, for specific amplification HLA-A*24:02 gene and HLA-B*15:02 gene.
In a preferred embodiment of the present invention, in test kit, the concentration of every primer is 10pmol/l.
Another aspect of the present invention provides primer sets of the present invention and is combined in the SJS/TEN's that preparation detection AEDs causes Application in test kit, this primer sets shares in specific amplification HLA-A*24:02 gene and HLA-B*15:02 gene.
Further aspect of the present invention provides primer combination of the present invention, or test kit of the present invention is in detection Application in the SJS/TEN that AEDs causes, the combination of this primer and test kit are used for specific amplification HLA-A*24:02 gene and HLA-B*15:02 gene.
The method that on the one hand present invention finally provides the SJS/TEN that a kind of detection AEDs causes, it comprises the steps of:
1st, obtain testing sample DNA.
2nd, adopt primer combination of the present invention, or adopt test kit of the present invention, with obtain in step 1 DNA is template, enters performing PCR amplification.
3rd, Sanger sequencing is carried out to pcr amplification product.
4th, after obtaining sequencing peak figure, carry out result interpretation, judge HLA-A*24 in testing sample:02 gene and HLA-B* 15:The positive rate of 02 gene.
In a preferred embodiment of the present invention, in step 2, the concentration of every primer is 10pmol/l.
In further preferred embodiment of the present invention, carry out purification after also including sequencing reaction in step 3 and enter The step of row degenerative treatments.
Seen from the above description, compared with prior art, the present invention possesses following advantage.
1st, the present invention adopts case-control study, carries out to taking SJS/TEN the and AEDs tolerance sample that AEDs leads to HLA-A site and HLA-B site carry out Sanger sequencing and typing, find HLA-A*24:02 leads in CBZ, LTG and PHT The positive rate of SJS/TEN, apparently higher than tolerance group, is the common risk factor of three kinds of medicines.The present invention is further discovered that HLA-A* 24:02 and HLA-B*15:The independent risks and assumptions of the SJS/TEN that 02 genotype causes for AEDs, and two genotype have Synergistic effect.
2nd, the present invention is according to HLA-A*24:02 and HLA-B*15:02 gene order, devising can efficiently specifically The primer of amplification both genes, has the specificity of height.And on this basis, devise and AEDs can be caused Test kit and method that SJS/TEN is detected.
3rd, detection method joint-detection HLA-A*24 of the present invention:02 and HLA-B*15:02 gene, can be respectively increased To 82.1% and 70.6%, specificity is tri- kinds of drug induced sensitivity of SJS/TEN and CBZ/LTG/PHT that CBZ leads to 70.6% and 69%.Meanwhile, the detection method of the present invention passes through joint-detection HLA-A*24:02 and HLA-B*15:02 gene, with The SJS/TEN that prediction AEDs leads to, can reduce the incidence rate of southern Chinese Han Population SJS/TEN, be reduced to from 35.8/100000 13.0/100000.
Brief description
Fig. 1:The agarose gel electrophoretogram of pcr amplification product.
Fig. 2:A2F sequencing peak shape figure.
Fig. 3:A2R sequencing peak shape figure.
Fig. 4:A3F sequencing peak shape figure.
Fig. 5:A3R sequencing peak shape figure.
Fig. 6:A4F sequencing peak shape figure.
Fig. 7:B2F sequencing peak shape figure.
Fig. 8:B2R sequencing peak shape figure.
Fig. 9:B3F sequencing peak shape figure.
Figure 10:B3R sequencing peak shape figure.
Figure 11:B4F sequencing peak shape figure.
Specific embodiment
Below by embodiment, the present invention is described in further detail it is intended to be used for illustrating rather than restriction originally Invention.It should be pointed out that to those skilled in the art, under the premise without departing from the principles of the invention, can also be to this Bright carry out some improve and modify, these improve and modify similarly fall under the scope of the present invention.
Embodiment 1:Sample collection
Gather and in 8 weeks, take 91 (i.e. cases of patient that SJS/TEN untoward reaction in anti-aromatic series AED first Group) and take the individuality 322 (i.e. antiepileptic tolerance matched group) that antiepileptic skin adverse reaction for 3 months Peripheral blood, take 4ml, -80 DEG C of Refrigerator stores with EDTA anticoagulant tube.
Case group and matched group crowd are Han population of South China, and the nationality of proprietary grand parents, grand parents Pass through and be southern area of China.
Embodiment 2:Experimental technique flow process
1st, DNA extraction
Extract people periphery using Quickgene DNA extraction agent box and supporting Quickgene-610LDNA extractor Blood leukocytes DNA, step is carried out by operating instruction.Comprise the following steps that:
A, to 15ml centrifuge tube add 300 μ l protease (EDB), 2ml human peripheral specimen, 2.5mL lysis buffer (Lysis Buffer,LDB);
B, mixing 10-15 time of turning upside down;
C, eddy mixer 2500rpm/ divide × 15 seconds;
D, 56 DEG C of water-baths 5 minutes;
E, addition dehydrated alcohol 2.5mL;
F, mixing 10-15 time of turning upside down;
G, eddy mixer 2500rpm/ divide × 15 seconds;
H, pour the mixture into Quickgene 20ml purification column jecket;
I, for the first time operation " DNA WHOLE BLOOD " pattern, run " ISOLATE A " pattern second, can obtain two pipes Required human peripheral leucocytes DNA;
Using concentration and the OD value of spectrophotometric determination DNA after J, fully mixing;Each specimen genomic DNA of gained OD260/OD280It is respectively positioned between 1.7-2.0, DNA concentration is no less than 50ng/ul, total amount is no less than 10 μ g.
K, it is placed in -20 DEG C of Refrigerator stores.
2nd, design of primers, pcr amplification reaction and purification
The gene order announced according to GenBank, using the design of Primer Premier 5.0 primer-design software, by giving birth to Work biological engineering (Shanghai) limited company synthesizes.For reducing sequencing peak figure bottom peak, ensure sequencing primer to greatest extent Purity, by the optimization of primer reaction condition with compare, filter out the primer of high specificity.Specific primer sequence is referring to table 1.
Table 1:The amplimer sequence table of HLA-A and HLA-B gene
The PCR reaction system of each genomic DNA sample, performing PCR of going forward side by side in 96 hole Sptting plates, is prepared respectively according to table 2 Reaction.
Table 2 PCR amplification system
PCR response procedures are as follows:96 DEG C of denaturations 5min;98 DEG C of degeneration 10s, 65 DEG C of annealing 30s, 72 DEG C of extension 60s, 5 Individual circulation;96 DEG C of degeneration 20s, 60 DEG C of annealing 30s, 72 DEG C of extension 60s, 30 circulations;72 DEG C of extension 10min.4 DEG C of preservations.
Amplified production electrophoresis pattern is referring to accompanying drawing 1.
Product utilization SAP after amplification carries out purification.
3rd, Sanger sequencing and typing
Sanger be sequenced with ABI company Big Dye Terminator V3.1 as main agents (containing dNTP, ddNTP and Fluorescein), it is template with the product after front PCR reaction purification, add specific primer to be circulated amplification.HLA-A、HLA-B Sequencing primer be respectively A-2F/R, A-3F/R, A-4F, B-2F/R, B-3F/R, B-4F.Specific sequencing primer sequence referring to Table 3.
Table 3 sequencing reaction amplimer sequence table
Sequencing primer site Sequence
A2F CCTCTGYGGGGAGAAGCA
A2R TCTCGGACCCGGAGACTG
A3F CATTTTCAGTTTAGGCCAAAAAT
A3R CCAATTGTCTCCCCTCCTTG
A4F GGGTGTCCTGTCCATTCTCA
B2F AGGAGCGAGGGGACCGCA
B2R GATCTCGGACCCGGAGACT
B3F GGGGCCAGGGTCTCACA
B3R TGGGAGGCCATCCCCGGC
B4F GGTCACATGGGTGGTCCTAG
The reaction condition of sequencing amplification is as follows:96℃2min;96 DEG C of 10s, 50 DEG C of 20s, 60 DEG C of 2min (25 circulations);15 ℃∞.
The reaction system of sequencing amplification is 5ul, and as shown in table 4, wherein 2.5 × Bigdye and 5 × Buffer is equal for its composition Purchased from Applied biosystems (Applied Biosystems, ABI).
Table 4 sequencing reaction system
Sequencing amplified production is through ethanol EDTA-Na2After deposition and purification is processed, dissolve degeneration with deionized formamide, ABI 3730xl full-automatic DNA sequencer (U.S.) capillary electrophoresis simultaneously are analyzed to result processing automatically, obtain desirable tablet Section base sequence, and presented with 4 color peak figure forms.Using the sequence to HLA-A, HLA-B for Vector NTI 6.0 (U.S.) software Row are according to http:The online sequence announced of //www.ebi.ac.uk/imgt/hla is compared and is obtained result.
4th, statistical analysiss and result
Statistical analysiss are carried out using SPSS 16.0 statistical analysis software.
HLA-A*24 by case group and matched group:02 and HLA-B*15:02 positive rate chi-square criterion or exact probability Method is compared, and P 0.05 is that difference is statistically significant, shows HLA-A*24:02 is the risk genes of CBZ, LTG and PHT, Also it is the common risk gene of three kinds of medicines simultaneously;HLA-B*15:02 is the risk genes of CBZ, is also three kinds of medicines simultaneously Common risk gene (concrete data is referring to table 5).
Table 5:The SJS/TEN risks and assumptions that CBZ, LTG, and PHT lead to
The reciprocal action of the SJS/TEN being led in AEDs using two allele of Logtistic analysis of regression model, is entered Enter standard α=0.05 of equation, reject equation standard α=0.10, P<0.05 has statistical significance for difference, is retained in Factor in Logistic regression model is defined as meaningful risk factor, finds that two genes are independent risk genes, and has There is cumulative benefit (concrete data is referring to table 6).
Table 6:HLA-B*15:02 and HLA-A*24:The SJS/TEN accumulative effect that 02 couple of AED leads to
It is 35.8/100000ths according to three kinds of drug induced SJS incidence rates, detect HLA-A*24:02 and HLA-B*15: 02 genotype, HLA-A*24:02 gene masculine or HLA-B*15:02 positive patient avoids taking these three AEDS, can reduce SJS incidence rate is to 13/100000ths.

Claims (10)

1. a kind of primer combination for detecting SJS/TEN that AEDs causes, its primer shown in sequence 1-4 forms, and is used for Specific amplification HLA-A*24:02 gene and HLA-B*15:02 gene.
2. primer combination according to claim 1, it is made up of 2 groups of primers further, and the 1st group shown in sequence 1 and 2 Primer forms, for specific amplification HLA-A*24:02 gene, the 2nd group of primer shown in sequence 3 and 4 forms, for special Property amplification HLA-B*15:02 gene.
3. primer combination according to claim 1 and 2, the concentration of wherein every specificity amplification primer is 10pmol/ l.
4. a kind of test kit for detecting SJS/TEN that AEDs causes, it comprises drawing any one of claim 1-3 Thing combines, for specific amplification HLA-A*24:02 gene and HLA-B*15:02 gene.
5. test kit according to claim 4, the concentration of wherein every primer is 10pmol/l.
6. the primer sets any one of claim 1-3 are combined in the test kit of SJS/TEN that preparation detection AEDs causes Application, described primer sets share in specific amplification HLA-A*24:02 gene and HLA-B*15:02 gene.
7. the primer combination any one of claim 1-3, or the test kit described in claim 4 or 5 is in detection Application in the SJS/TEN that AEDs causes, described primer combination or test kit are used for specific amplification HLA-A*24:02 gene and HLA-B*15:02 gene.
8. the method for the SJS/TEN that a kind of detection AEDs causes, it comprises the steps of:
(1) obtain testing sample DNA;
(2) adopt the primer combination any one of claim 1-3, or using the test kit described in claim 4 or 5, The DNA being obtained with step (1), as template, enters performing PCR amplification;
(3) Sanger sequencing is carried out to pcr amplification product;
(4), after obtaining sequencing peak figure, carry out result interpretation, judge HLA-A*24 in testing sample:02 gene and HLA-B*15:02 The positive rate of gene.
9. in method according to claim 8, wherein step (2), the concentration of every primer is 10pmol/l.
10. carry out purification after also including sequencing reaction in method according to claim 8 or claim 9, wherein step (3) and enter The step of row degenerative treatments.
CN201610832567.4A 2016-09-20 2016-09-20 Primers, kit and method for detection of SJS/TEN caused by AEDs Pending CN106399503A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610832567.4A CN106399503A (en) 2016-09-20 2016-09-20 Primers, kit and method for detection of SJS/TEN caused by AEDs

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201610832567.4A CN106399503A (en) 2016-09-20 2016-09-20 Primers, kit and method for detection of SJS/TEN caused by AEDs

Publications (1)

Publication Number Publication Date
CN106399503A true CN106399503A (en) 2017-02-15

Family

ID=57996990

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201610832567.4A Pending CN106399503A (en) 2016-09-20 2016-09-20 Primers, kit and method for detection of SJS/TEN caused by AEDs

Country Status (1)

Country Link
CN (1) CN106399503A (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI650423B (en) * 2017-10-27 2019-02-11 長庚醫療財團法人林口長庚紀念醫院 Risk assessment for lamotrigine-induced cutaneous adverse drug reactions and detecting agent thereof and use thereof
CN109628575A (en) * 2019-01-07 2019-04-16 复旦大学附属华山医院 Application of the HLA-A*24:02 allele in the drug rash risk caused by the raw metronidazole of detection human hair
CN113278687A (en) * 2021-05-20 2021-08-20 广州医科大学附属第二医院 Kit for detecting HLA-B1502 and HLA-A2402 genotypes

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101353698A (en) * 2008-03-21 2009-01-28 广州医学院第二附属医院 Reagent for detecting antiepileptic drug allergic reaction associated antigen genetype and clinical application method
CN102108382A (en) * 2009-12-23 2011-06-29 上海主健生物工程有限公司 Genetic testing for risk of causing serious adverse reactions of skin of carbamazepine
CN103045591A (en) * 2013-01-05 2013-04-17 上海荻硕贝肯生物科技有限公司 HLA gene specific PCR amplification primer, HLA typing method and kit
CN104024410A (en) * 2011-12-28 2014-09-03 凸版印刷株式会社 Method for determining HLA-A*24 group
CN104818316A (en) * 2013-11-28 2015-08-05 复旦大学 Human leukocyte antigen gene detection kit for screening skin drug adverse reactions caused by salazosulfapyridine
CN105039579A (en) * 2011-06-23 2015-11-11 长庚医疗财团法人基隆长庚纪念医院 Method for evaluating drug anaphylactic reaction caused by antiepileptic drug phenytoin with HLA allele

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101353698A (en) * 2008-03-21 2009-01-28 广州医学院第二附属医院 Reagent for detecting antiepileptic drug allergic reaction associated antigen genetype and clinical application method
CN102108382A (en) * 2009-12-23 2011-06-29 上海主健生物工程有限公司 Genetic testing for risk of causing serious adverse reactions of skin of carbamazepine
CN105039579A (en) * 2011-06-23 2015-11-11 长庚医疗财团法人基隆长庚纪念医院 Method for evaluating drug anaphylactic reaction caused by antiepileptic drug phenytoin with HLA allele
CN104024410A (en) * 2011-12-28 2014-09-03 凸版印刷株式会社 Method for determining HLA-A*24 group
CN103045591A (en) * 2013-01-05 2013-04-17 上海荻硕贝肯生物科技有限公司 HLA gene specific PCR amplification primer, HLA typing method and kit
CN104818316A (en) * 2013-11-28 2015-08-05 复旦大学 Human leukocyte antigen gene detection kit for screening skin drug adverse reactions caused by salazosulfapyridine

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI650423B (en) * 2017-10-27 2019-02-11 長庚醫療財團法人林口長庚紀念醫院 Risk assessment for lamotrigine-induced cutaneous adverse drug reactions and detecting agent thereof and use thereof
CN109628575A (en) * 2019-01-07 2019-04-16 复旦大学附属华山医院 Application of the HLA-A*24:02 allele in the drug rash risk caused by the raw metronidazole of detection human hair
CN109628575B (en) * 2019-01-07 2021-11-05 复旦大学附属华山医院 Use of HLA-A24: 02 allele for detecting the risk of a human developing drug eruption due to metronidazole
CN113278687A (en) * 2021-05-20 2021-08-20 广州医科大学附属第二医院 Kit for detecting HLA-B1502 and HLA-A2402 genotypes
CN113278687B (en) * 2021-05-20 2023-11-24 广州医科大学附属第二医院 Kit for HLA-B1502 and HLA-A2402 genotype detection

Similar Documents

Publication Publication Date Title
CN107190064B (en) SnaPshot kit for detecting polymorphism of 22-site deafness genes
CN106591473B (en) A kind of people MTHFR and MTRR genetic polymorphism detections primer, probe, kit and method
CN102534031B (en) High-specificity kit for detecting deafness predisposing genes and uses
CN103911452A (en) Chinese population deaf gene screening kit and application thereof
CN106399503A (en) Primers, kit and method for detection of SJS/TEN caused by AEDs
CN103451302A (en) Deafness susceptible gene mitochondrion 12SrDNA 1555A&gt;G and 1494C&gt;T mutant ratio detection kit
CN113584147A (en) Gene polymorphism detection kit for guiding medication of psychosis
CN106148550B (en) Application of single nucleotide polymorphism rs1800796 locus in detecting susceptibility of ATDH
CN105255869B (en) Application of ABCC4 gene polymorphism site rs3742106 and detection primer and kit thereof
CN106282329A (en) A kind of helicobacter pylori gyrA gene mutation detection kit and detection method thereof
CN102586433B (en) Deafness predisposing gene 12S rRNA (ribosomal ribonucleic acid) 1494C&gt;T fluorescence detection kit and application thereof
CN104774918A (en) IL28B gene polymorphism detection kit based on real-time fluorescent PCR
CN104388553B (en) The detection primer of myodystony VPS16 genes, method and kit
CN104164505B (en) A kind of for detecting the syndromic test kit of VKH
CN102534030B (en) Kit for jointly detecting four deafness predisposing genes and application thereof
Spotin et al. Molecular Characterization of Trichomonas vaginalis strains based on identifying their probable variations in asymptomatic patients
CN108018355A (en) Detection kit and its preparation and purposes based on VDR gene pleiomorphism auxiliary diagnosis Huppert&#39;s diseases
CN106191299A (en) For detecting primer, test kit and the method for SCN1A gene 5 &#39; end non-coding mutation
CN102660636A (en) A fluorescence detection kit for detecting deafness susceptibility gene 12S rRNA 1555A&gt;G and application thereof
CN110923312A (en) Real-time fluorescent PCR method for detecting rs762551 site of CYP1A2 gene and primer probe combination thereof
CN107083429B (en) A kind of SNP parting kit and its application for the detection of atrial fibrillation tumor susceptibility gene
CN107893117A (en) Detect the method and primer of the full extron of IL7R genes
CN110387413B (en) Application of lncRNA TRAM2 as glaucoma diagnostic marker
CN112626204B (en) Primers and method for detecting HLA-B1502 typing useful for guiding administration of carbamazepine
Taleb et al. Molecular Characterization of Erythrocyte Glucose-6-Phosphate Dehydrogenase Deficiency in Different Ethnic Groups of Blood Donors in Mauritania

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination